The Management of Resistant Hypertension in Kidney Transplant Patients Using Chlorthalidone

Withdrawn before enrolling · Phase 4

Conditions studied: Resistant Hypertension in Kidney Transplant Patients

In brief

Chlorthalidone might offer an effective, safe and inexpensive anti-hypertensive treatment for kidney transplant patients who have resistant hypertension on multi-drug therapy. We will collect initial data on the safety and efficacy of Chlorthalidone in the treatment of patients with resistant hypertension. To Examine the efficacy of chlorthalidone as an anti-hypertensive agent in the treatment of resistant hypertension among stable kidney transplant recipients

Key facts

Study ID

NCT02030314

Run by

Virginia Commonwealth University

People needed

0

Starts

2013-07-01

Expected to finish

2017-04-12

Last updated by the study team

2017-06-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Agree to participate in study
• Patients after kidney transplantation> 6 months post-transplant.
• Age>18 years
• Home or office Systolic Blood pressure >140 confirmed with daytime 24-h ABPM of average systolic blood pressure >140.
• Tacrolimus/Cyclosporine therapy with therapeutic trough level based upon historical values
• Stable renal function for at least 3 months before enrollment.
• Historical Baseline estimated Glomerular Filtration Rate >30mL/min
• No more than trace edema on physical examination at time of initial assessment.
• Receiving optimal doses of ≥ 3 anti-hypertensive medications including furosemide at ≤80mg/d.9.
• 8-10 in morning sitting Plasma aldosterone Concentration < 15ng/dL and Plasma Renin Activity <0.6ng/mL/h

You may not qualify if…

• Serum sodium<135meq/L based upon historical values
• Serum potassium<3.5meq/L based upon historical values
• Poorly controlled diabetes mellitus with HbA1c>9% based upon historical values
• Already on thiazide
• Arm circumference >42cm
• Clinically significant hepatic dysfunction based upon medical history or historical values
• Two (2) Unsuccessful baseline ABPMs
• Poor adherence in run-in period as suggested by an unsuccessful 24-h urine collection.
• DBP≥110 or SBP≥200
• Allergy to Chlorthalidone

Where it is running

• Virginia Commonwealtlh University — Richmond, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.